Marcia S. Brose, MD, PhD, discusses 2 patient cases of differentiated thyroid cancer (DTC) and explains the DTC treatment landscape.
EP. 1: Patient Case 1: A 70-Year-Old Woman with Differentiated Thyroid Cancer
Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).
EP. 2: Defining RAI-Refractory Differentiated Thyroid Cancer
Dr Brose delves into radioiodine-refractory differentiated thyroid (RR-DTC), from its definition and the clinical molecular markers that impact that refractoriness.
EP. 3: Frontline Treatment Options in RR-DTC
Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).
EP. 4: Lenvatinib and Age
An expert explains the impact of patient age when taking lenvatinib for treatment.
EP. 5: Study 211 and HRQoL: Lenvatinib and RR-DTC
A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.
EP. 6: Treating DTC With Lenvatinib
Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.
EP. 7: Patient Case 2: A 57-Year-Old Man With DTC
Marcia S. Brose, MD, PhD, introduces our second patient case, a 57-year-old man with DTC.
EP. 8: Lung Metastases and DTC
A medical professional explains how the size of lung metastases affect the treatment of DTC and clinician decision-making.
EP. 9: Second-Line Treatment Options
An expert briefly discusses the second-line treatment options for patients with DTC that have progressed on first-line therapy.
EP. 10: Future Directions and Unmet Needs in Treating DTC
Marcia S. Brose, MD, PhD, concludes by listing some future directions she’d like to see within the treatment landscape, as well unmet needs that she hopes will be considered.
2 Clarke Drive Cranbury, NJ 08512